impact of targeted therapies on treatment of mds and aml
Published 6 years ago • 585 plays • Length 5:17Download video MP4
Download video MP3
Similar videos
-
6:50
the role of bmt in treatment-related mds and aml
-
9:29
mds/aml overlap and novel therapies with dr. naval daver
-
8:11
non transplant treatments for mds & secondary aml (co-chair summary)
-
4:50
mds & aml: implications of genetic mutations for management
-
1:41
the future of aml and mds diagnosis and treatment
-
34:15
from mds to aml: what every patient needs to know 11/28/17
-
15:30
treatments for mds and secondary aml, with drs o. odenike and d. sallman
-
1:28
cd47 antibodies for the treatment of aml and mds: where is the field moving?
-
11:49
2022 scientific symposium highlights for patients: treatments for mds and secondary aml
-
1:13:29
understanding higher risk mds and transtion to aml
-
25:33
mds – new and emerging treatments
-
54:20
2019 research updates on mds and aml from eha and asco
-
1:13
expanding treatment options for aml to patients with mds
-
55:36
short telomere syndrome implications for mds and aml patients
-
6:58
mds and aml biology (co-chair summary)
-
50:26
mds - aml - 2020 spring virtual conference: when mds becomes aml - for high-risk mds patients
-
1:32:06
high risk mds treatment strategies
-
53:40
aamdsif 40th anniversary summit: advances in the science and treatment of mds
-
1:29:30
myelodysplastic syndromes and secondary aml– update on diagnosis and treatment